Gilotrif (Afatinib)

Gilotrif is called Giotrif and Xovaltib interationally.  Save over 95% with generic versions of Gilotrif and over 60% on the European brand versions.

Click here for information on Natco generics (Immediate availability)

Xovaltib is English packaging.  Other versions are non-English but will include English labels and inserts.

According to the European Medicines Agency, Boehringer manufactures originating from Europe product manufactured at the following site(s):Boehringer Ingelheim Pharma GmbH & Co. KG Binger Strasse 173 55216 Ingelheim am Rhein GermanyBoehringer Ingelheim France 100-104 Avenue de France 75013 Paris France

Information about Gilotrif (Afatinib)

Gilotrif is an oral medication that acts as a targeted therapy for certain types of non-small cell lung cancer (NSCLC). It is a tyrosine kinase inhibitor (TKI) that specifically targets the epidermal growth factor receptor (EGFR) mutations that drive cancer cell growth.

Product Highlights

• FDA-approved for patients with metastatic NSCLC with specific EGFR mutations.
• Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have specific EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

Key Ingredient

• Afatinib

Key Benefits

• Effective in shrinking tumors and improving progression-free survival in patients with EGFR-mutated NSCLC.
• Can be taken as a once-daily oral therapy, which enhances patient convenience.
• Has shown efficacy in both treatment-naive patients and those who have progressed on prior therapies.

Direction of Use

• Administer one tablet daily, with or without food.
• Take the tablet whole; do not chew or crush it.
• Adhere to the prescribed dosage and consult a healthcare provider for any necessary adjustments.

Safety Concerns

• Common side effects include diarrhea, rash, stomatitis, and decreased appetite.
• Monitor for serious adverse effects such as interstitial lung disease (ILD) and liver function abnormalities.

Avoid Gilotrif (Afatinib) If

• You have a known hypersensitivity to afatinib or any of its components.
• You have a history of severe pulmonary disease or ILD.
• You are pregnant, planning to become pregnant, or breastfeeding without first discussing it with a healthcare provider.